Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer
Abstract
Background In murine studies, we demonstrated that a DNA vaccine encoding the androgen receptor (pTVG-AR) given prior to androgen deprivation elicited prostate tumor-infiltrating lymphocytes and an antitumor response. The current trial evaluated this approach, with or without programmed cell death protein-1 (PD-1) blockade, in patients with high-risk newly diagnosed prostate cancer. Methods In the first stage of a two-stage protocol, 24 patients were randomized to treatment with (1) degarelix alone (n=6); (2) pTVG-AR followed by degarelix (n=9); or (3) pTVG-AR, degarelix and nivolumab (n=9), each delivered over 12 weeks prior to prostatectomy. The primary objectives were safety and pathological complete response or minimal residual disease (MRD). Secondary endpoints were residual cancer burden (RCB)
Fields of Study & Subjects
Prostate Cancer Treatment and Research
Immunotherapy and Immune Responses
Cancer Immunotherapy and Biomarkers
Publication details
- Journal / source
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Volume
- 14
- Issue
- 3
- Pages
- e013790–e013790
- Publication date
- 1 March 2026
- Language
- EN